Compare DexCom, Inc. (DXCM) vs Schlumberger NV (SLB) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

SLB trades at $47.21, down 0.69% on the day, with a bullish technical signal supported by moving averages. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $0.52. Recent strategic alliances with Liberty Energy for data center power solutions and major contract wins like the Baleine Phase 3 EPC deal highlight growth initiatives. Valuation metrics show a P/E of 20.95 and P/S of 1.95, while profitability remains solid with a net income margin of 9.26% and ROE of 14.57%.

The outlook for SLB is positive, driven by contract expansions and diversification into data center infrastructure, offering upside to the $62.83 consensus price target. Risks include oil price volatility and execution challenges in new ventures. Analyst sentiment is strongly bullish with 84.85% buy ratings, though investors should monitor debt levels and macroeconomic pressures on energy demand.